Pure Biologics S.A. (WSE:PUR)
Poland · Delayed Price · Currency is PLN 3.584
-0.016 (-0.44%)
At close: Feb 12, 2026
Pure Biologics Company Description
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use.
Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin.
The company was founded in 2010 and is based in Wroclaw, Poland.
Pure Biologics S.A.
| Country | Poland |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Filip Jelen |
Contact Details
Address: Szczytnicka 11 Wroclaw, 50-382 Poland | |
| Phone | 48 57 000 2829 |
| Website | purebiologics.com |
Stock Details
| Ticker Symbol | PUR |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLPRBLG00010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Filip Jelen M.B.A., Ph.D. | Co-founder and President of the Management Board |
| Przemyslaw Dudek | Head of Information Technology |
| Dr. Ewelina Swiderek Ph.D. | Head of Project Management |